Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NNC6022-0001 · 1 trial · 2 indications
Number of events
| Arm | Type | Description |
|---|---|---|
| NNC6022-0001 | EXPERIMENTAL | Participants will be randomised to NNC6022-0001. |
| Placebo (NNC6022-0001) | PLACEBO_COMPARATOR | Participants will be randomised to placebo. |
| Name | Type | Description |
|---|---|---|
| NNC6022-0001 | DRUG | Participants will recieve single ascending dose (SAD) of NNC6022-0001. Dose is given in escalating manner for up to seven cohorts. |
| Placebo (NNC6022-0001) | DRUG | Participants will recieve single ascending dose (SAD) of placebo. Placebo is given in escalating manner for up to seven cohorts |
Inclusion Criteria: 1. Men or women of non-childbearing potential. 2. Age 18-55 years (both inclusive) at the time of signing the informed consent. 3. Body mass index (BMI) between 18.5 to 29.9 kg/m\^2 (both inclusive) at screening. 4. Body Weight: Greater than or equal to 50 kg at screening. 5. Co...
NNC6022-0001 is an investigational small molecule medicine being developed by Novo Nordisk A/S for cardiovascular and cardiometabolic conditions. It has been studied in a Phase 1 clinical trial in healthy volunteers. The specific disease indication it is intended to treat has not been publicly disclosed.
NNC6022-0001 is being developed by Novo Nordisk A/S, which trades on the New York Stock Exchange under the ticker NVO. The company sponsored the Phase 1 study of the compound conducted in the Netherlands.
NNC6022-0001 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no trials are currently active. The compound is investigational and has not been approved by the FDA or any other regulatory agency.
NNC6022-0001 has been evaluated in one Phase 1 trial, NCT06336005, titled A Study to See How Safe a New Medicine (NNC6022-0001) is in Healthy People. The trial enrolled 56 healthy adult volunteers in the Netherlands, was randomized, double-blind, and placebo-controlled, and is now completed.
The Phase 1 trial NCT06336005 was a randomized, double-blind, placebo-controlled study of NNC6022-0001 in healthy volunteers. It enrolled 56 participants of any sex, aged 18 years and older, across sites in the Netherlands. The study has been completed.